Abstract
Background. This cross-sectional study aimed to investigate the relationship between exposure to anticholinergic and sedative medications, measured with the Drug Burden Index (DBI), and functional outcomes in community-dwelling older people living in Finland.
Methods. The study population consisted of community-dwelling older people (n = 700) enrolled in the Geriatric Multidisciplinary Strategy for the Good Care of the Elderly (GeMS) study. Outcomes included walking speed, chair stands test, grip strength, timed up and go (TUG) test, instrumental activities of daily living (IADL), and Barthel Index.
Results. Exposure to DBI drugs was identified in 37% of participants: 24% had a DBI range between >0 <1, and 13% DBI ≥1. After adjusting for confounders, exposure to DBI drugs was associated with slower walking speed (P < 0.0001), poorer performance on chair stands (P = 0.0001) and TUG (P < 0.0001), difficulties in IADL (P < 0.0001), and Barthel Index (P < 0.0001). The mean adjusted walking speed, time to complete chair stands and TUG, IADL, and Barthel scores were significantly poorer among participants with higher DBI ranges.
Conclusion. In older adults living in Finland, DBI was associated with impaired function on previously tested and new outcomes. This finding supports the use of the DBI as tool, in combination with other assessments, to identify older people at risk of functional impairment. The findings highlight the need for revision of current guidelines to improve the quality of drug use in older people.
Acknowledgements
The authors gratefully acknowledge the funding support from the Geoff and Elaine Penney Ageing Research Unit, and the Scientific Staff Council, Royal North Shore Hospital, Sydney, Australia. The authors also thank the Social Insurance Institution of Finland and City of Kuopio for supporting the Geriatric Multidisciplinary Strategy for the Good Care of the Elderly (GeMS) Study. No other sources of funding were used to assist in the preparation of the manuscript.
Declaration of interest: Dr Hilmer holds an international patent for the Drug Burden Index with Drs Abernethy and Mager.